Switzerland in talks with US as cost of F-35A fighter jets rises
By John Revill and Marleen Kaesebier
ZURICH (Reuters) -Switzerland is holding talks with the United States after Washington tried to raise the price of new fighter jets Bern is buying for its air force, the government said on Wednesday.
Bern chose Lockheed Martin's F-35A Lightning II as its next-generation fighter plane in 2021, with a fixed price of around 6 billion Swiss francs ($7.4 billion) for 36 jets, a decision that attracted controversy in neutral Switzerland.
But the U.S. Joint Program Office overseeing the project said last year the price could be higher, and the U.S. Defense Security Cooperation Agency told Switzerland in February that the fixed price was a misunderstanding.
Switzerland was informed the price for the F-35s would be dearer because of higher raw materials and energy costs, as well as higher U.S. inflation, with the sum potentially increasing by $650 million to $1.3 billion, the government said.
"A contract is a contract," said Urs Loher, head of Swiss defence procurement agency Armasuisse. "With the procurement of the F-35A fighter aircraft, we're suddenly faced with a different reality, despite a clear fixed price."
As the agreement prevents a legal settlement of the dispute, a diplomatic solution must be sought, the government said.
Defence Minister Martin Pfister said talks were now under way with the U.S. authorities.
"We still believe we'll find a solution with the U.S. authorities because they also have an interest in being perceived as a reliable contractual partner," Pfister said, while as a last resort Switzerland could cancel the deal.
The decision to buy the F-35A was contested in Switzerland, with opponents arguing against replacing the country's aging F/A-18 jets with an unnecessary "Ferrari" option. Critics said Switzerland did not need cutting-edge warplanes to defend its territory, which a supersonic jet can cross in 10 minutes.
The F-35A beat bids from Boeing's F/A-18 Super Hornet, the Rafale produced by France's Dassault and the four-nation Eurofighter built by Italy's Leonardo, Britain's BAE Systems and Airbus representing Germany and Spain.
Still, Switzerland said it remained committed to the F-35A, and that cancelling the order would have serious consequences.
"Switzerland would no longer be able to guarantee the safety of its airspace and population from 2032, as the current F/A-18 fighter aircraft would reach the end of their service life," Pfister said.
($1 = 0.8067 Swiss francs)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced its participation at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society, a leading Ataxia-Telangiectasia (A-T) patient advocacy group based in the United Kingdom. Taking place June 25-27, 2025 at Loughborough University in the U.K., key opinion leaders (KOLs) will present post hoc data analyses from the company's prior Phase 3 ATTeST clinical trial of its lead asset, eDSP, for the treatment of patients with A-T. Additionally, Quince management will provide an overview of its pivotal Phase 3 NEAT clinical trial. Highlights of A-T Clinical Research Conference Presentations KOLs will present the following data and information at the upcoming A-T Clinical Research Conference: Endocrine and Metabolic Events in Patients with A-T Treated with eDSP: William Whitehouse, M.D., Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, England, recently retired Consultant Pediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, and current Quince Scientific Advisory Board member, will provide a presentation titled Endocrine and Metabolic Events in Children with Ataxia-Telangiectasia Treated Long-term with Erythrocyte-Delivered Encapsulated Dexamethasone Sodium Phosphate (eDSP). The objective of the data analysis was to evaluate metabolic and endocrine adverse events (AEs), growth, and safety laboratory results in patients with A-T treated with eDSP. Key findings reported in Dr. Whitehouse's presentation highlighted that there were no reports of serious metabolic or endocrine events in the 68 patients with A-T treated with eDSP for two years or longer. Growth in height of these patients was also preserved. MiniATM Family Expression in Patients with A-T Treated with eDSP: Michele Menotta, Ph.D., Associate Professor in the Department of Biomolecular Sciences at the University of Urbino in Urbino, Italy, will provide a presentation titled MiniATM Family Expression in ATTeST: Molecular Insights into Unusual ATM Variants in A-T Cells. The objective of the data analysis investigates the potential relationship between miniATM family expression in the blood of patients with A-T who participated in Quince's prior Phase 3 ATTeST clinical trial and their corresponding neurological scores. Additionally, novel functions of the miniATM family were explored in A-T cells and its molecular mechanism of action was investigated. The analysis found that miniATM genes were present in 40% of patients with A-T and were correlated with A-T disease severity at baseline. Lab tests also showed results that may variably influence cell processes, offering new insights for potential treatments. Pivotal Phase 3 NEAT Enrollment Update Quince's management will provide an overview of the company's pivotal Phase 3 NEAT (N eurologic E ffects of e DSP on Subjects with A - T; #IEDAT-04-2022 / NCT06193200) clinical trial and latest enrollment update at the A-T Society meeting. A total of 99 participants have been enrolled to date, including 78 participants in the six to nine year-old primary analysis population and 21 participants aged 10 years or older. All 42 NEAT participants to date have elected to transition to the NEAT open label extension (OLE) study (NCT06664853 / IEDAT-04-2022). Quince is currently enrolling a pivotal Phase 3 NEAT clinical trial, which is an international, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the neurological effects of eDSP (previously referred to as EryDex) treatment in patients with A-T. The company expects to report topline results in the first quarter of 2026 with a potential New Drug Application (NDA) submission to the FDA in the second half of 2026, assuming positive study results. Quince was granted Fast Track designation by the FDA for the company's eDSP System for the treatment of patients with A-T based on the potential for eDSP to address a high unmet medical need. About Ataxia-Telangiectasia A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene, which is responsible for cell homeostatic and cell division functions including but not limited to double-stranded DNA repair. Typically, A-T is first diagnosed before the age of five as children begin to develop an altered gait and fall with greater frequency. Neurological symptoms worsen and patients with A-T frequently become wheelchair-bound by adolescence. Teenage years for patients with A-T are typically marked by repeated infections, pulmonary impairment, and malignancies. The median lifespan is approximately 25 to 30 years old with mortality due to infections and malignancy. Based on IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics information, there are approximately 4,600 diagnosed patients with A-T in the U.S. Quince estimates that there are approximately 5,000 patients with A-T in the U.K. and EU4 countries. There are currently no approved therapeutic treatments in any global market for A-T. About eDSP for A-T eDSP is comprised of dexamethasone sodium phosphate (DSP) encapsulated in a patient's own red blood cells (autologous erythrocytes). DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. The eDSP System is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic use of corticosteroid treatment. eDSP leverages Quince's proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince's AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube. Forward-looking Statements Statements in this news release contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as 'believe,' 'may,' 'should,' 'expect,' 'anticipate,' 'plan,' 'believe,' 'estimated,' 'potential,' 'intend,' 'will,' 'can,' 'seek,' or other similar words. Examples of forward-looking statements include, among others, statements relating to the timing, success, and reporting of results of the clinical trials and related data, including plans and the ability to enroll participants, impact of closing enrollment, conduct, and/or complete current and additional studies; expected cash position and operating runway; ability to secure additional funding and financial support; current and future clinical development of eDSP, including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications; the strategic development path for eDSP; planned regulatory agency submissions and clinical trials and timeline, prospects, and milestone expectations; and the potential benefits of eDSP and the company's market opportunity. Forward-looking statements are based on Quince's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled 'Risk Factors' in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 13, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.
Yahoo
an hour ago
- Yahoo
Powell calls reports of lavish Fed building renovations inaccurate
By Michael S. Derby NEW YORK (Reuters) -Federal Reserve Chair Jerome Powell on Wednesday pushed back against reports the central bank was spending money excessively on renovations, saying that the almost 90-year-old headquarters "was not really safe," while acknowledging cost overruns. "The media reports ... are misleading and inaccurate in many, many respects," Powell said in an appearance before the Senate Banking Committee. Powell spoke as part of testimony for the central bank's semi-annual report on monetary policy to Congress. Senate Republican Tim Scott criticized the Fed over the renovations, saying at the hearing: 'During this time of hardship, the Fed has spent billions on lavish renovations to its D.C. offices.' Scott cited what he said were a series of luxury upgrades, coming at a time where the Fed has been in the unusual position of losing money due to its efforts to contain inflation pressures with high short-term interest rates. 'We can all agree that updating aging infrastructure is a legitimate need, but when senior citizens can barely afford Formica countertops, it sends the wrong message to spend public money on luxury upgrades that feel more like they belong in the Palace of Versailles than a public institution,' Scott said. Powell pushed back on the criticism. 'We do take seriously our responsibility as stewards of the public's money,' he said as he defended the need to upgrade the buildings the central bank counts as its headquarters for the Board of Governors. The Fed's 12 regional banks also have their own home bases. Powell said the Fed's Eccles building, constructed between 1935 and 1937, 'really needed a serious renovation,' saying that among the building's issues, 'it was not really safe and it was not waterproof.' He said reports of huge luxury upgrades were wrong and went on to detail what the Fed was doing to modernize the buildings. 'There are no new water features, there's no beehives, and there's no roof terrace gardens.' The Fed is also upgrading a building nearby. But Powell acknowledged that 'the cost overruns are what they are.' In a statement on its website, the Fed said the renovations 'will consolidate most Board staff into one campus; reduce off-site leases; and provide a modern, efficient workspace for employees to conduct their work on behalf of the American people.' Earlier this year, a report from the Federal Reserve's Inspector General, an in-house watchdog, said that as of February the cost of the renovations was expected to stand at $2.4 billion, up from $1.9 billion two years ago. The rise in costs comes as the Fed has faced notable and unprecedented losses due to how it manages monetary policy. The Fed is self-funded and earns income from bonds it owns and services it provides. The Fed has almost always been profitable but has not been in the last few years due to high interest rate costs aimed at setting rates to lower inflation pressures. The Fed deals with losses via accounting measures and has repeatedly noted the red ink does not impede its work, but those losses now have some elected officials targeting the system that led to the losses. (Reporting By Michael S. Derby and Dan Burns; Editing by Leslie Adler)
Yahoo
an hour ago
- Yahoo
Trump considers more Patriots for Ukraine, says Putin "has to end" the war
By Jeff Mason and Yuliia Dysa THE HAGUE (Reuters) -U.S. President Donald Trump indicated on Wednesday he will consider providing more of the Patriot missiles that Ukraine needs to defend against mounting Russian strikes, adding that Russian President Vladimir Putin "really has to end that war". His remarks came after a 50-minute meeting with Ukrainian President Volodymyr Zelenskiy on the sidelines of a NATO summit in The Hague. Both leaders described it as a positive step in a conflict that Trump described as "more difficult than other wars". During a press conference in which he celebrated his own diplomatic efforts in the Middle East, Trump said the Patriots were "very hard to get" but that "we are going to see if we can make some of them available". Zelenskiy mentioned air-defence systems but it was not immediately clear whether Trump was referring to more missiles or complete batteries. Trump also left open the possibility of providing more military aid to Kyiv, which has suffered grinding Russian advances on the battlefield in recent months. He had previously shown no sign of resuming the donations of weaponry to Ukraine that his predecessor Joe Biden had instituted after Russia launched its full-scale invasion in 2022. Asked directly whether the U.S. would contribute more funding to Ukraine's defence this year, Trump said: "As far as money going, we'll see what happens." The U.S.-made Patriot batteries are critical to shooting down the Russian ballistic missiles that have increasingly rained on Ukrainian cities in recent weeks. Dozens of people have been killed over the past week on the capital Kyiv and the southeastern regional capital of Dnipro. Zelenskiy said before Wednesday's meeting that Ukraine was willing to buy more Patriots if the U.S. was unwilling to donate them. He said the talks with Trump were "long and substantive". "Ukraine is ready to buy this equipment and support American weapons manufacturers," Zelenskiy wrote on X. "We also discussed the potential for co-production of drones. We can strengthen each other." Trump added that he would soon speak once more with Putin, adding: "Look, Vladimir Putin really has to end that war." MORE FORMAL LOOK FOR ZELENSKIY Zelenskiy wore a dark, suit-style jacket to the meeting, in contrast to the more informal military-style garb he was criticised for wearing at a disastrous White House meeting with Trump in February. He has since worked to rebuild relations with the Trump administration, whose overtures to Russia have concerned Kyiv. However, he had to settle for attending the pre-summit dinner on Tuesday evening rather than the main meeting on Wednesday, which backed the big NATO-wide increase in defence spending that Trump had demanded. Unlike last year, this year's summit declaration contained no mention of future NATO membership for Ukraine. While the statement denounced what it called the long-term threat posed by Russia to European and Atlantic security, it did not directly blame Russia for the invasion, as previous declarations have.
